GI clinical research 2002–2003: the year in review

Slides:



Advertisements
Similar presentations
Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado
Advertisements

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Manns.
Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
You Can Never Stop a Biologic
Masatoshi Kudo  Clinical Gastroenterology and Hepatology 
Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Ashwin N. Ananthakrishnan, Millie D. Long, Christopher F
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Charles D. Gerson, Mary-Joan Gerson 
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis 
Michael Camilleri, Anthony Lembo, David A. Katzka 
Unraveling the genetic predisposition of ribavirin-induced anaemia
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease  Stephen B Hanauer, Carrie L Wagner,
Short-Bowel Syndrome Clinical Gastroenterology and Hepatology
Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials  Stephen B Hanauer, Ulf Strömberg 
Fasiha Kanwal, MD, MSHS, Hashem B. El-Serag, MD, MPH 
Talya Salz, Robert S. Sandler  Clinical Gastroenterology and Hepatology 
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H
Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay?  Brian J. McMahon, MD, Brenna C. Simons, PhD  Clinical.
Volume 130, Issue 2, Pages (February 2006)
The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.
Michael Charlton  Clinical Gastroenterology and Hepatology 
Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice1   Thomas.
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Severe Constipation Clinical Gastroenterology and Hepatology
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab  Fernando.
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?  O.A. Cornely  Clinical Microbiology and.
Volume 119, Issue 6, Pages (December 2000)
Michael Camilleri, Allen W. Mangel, Sheri E. Fehnel, Douglas A
Volume 154, Issue 6, Pages (May 2018)
Volume 123, Issue 4, Pages (October 2002)
Volume 132, Issue 1, Pages (January 2007)
Issue Highlights Clinical Gastroenterology and Hepatology
Rafael Esteban, Maria Buti  Gastroenterology 
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg 
Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6
Long-term Outcome of Perianal Fistulizing Crohn's Disease Treated With Infliximab  Guillaume Bouguen, Laurent Siproudhis, Emmanuel Gizard, Timothée Wallenhorst,
Genetic Factors and Hepatitis C Virus Infection
Volume 121, Issue 5, Pages (November 2001)
Issue Highlights Clinical Gastroenterology and Hepatology
Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Nationwide Population- based Cohort Study With 30 Years of Follow-up Evaluation  Michael.
Volume 126, Issue 2, Pages (February 2004)
Hepatitis C treatment in patients with kidney disease
This Month in Gastroenterology
Christos Konstantakis, Maria Karamesini, Christos Triantos 
Volume 117, Issue 4, Pages (October 1999)
Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States  Zobair M. Younossi, Maria Stepanova 
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Novel Therapies for Hepatitis C Virus Based on Lessons From Virology
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.
Issue Highlights Clinical Gastroenterology and Hepatology
Volume 147, Issue 6, Pages (December 2014)
David S. Fefferman, Richard J. Farrell 
Masatoshi Kudo  Clinical Gastroenterology and Hepatology 
Robert G. Gish, Nezam H. Afdhal, Douglas T. Dieterich, K
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months  Gary R. Lichtenstein, Ole Ø. Thomsen,
Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,
Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.
Presentation transcript:

GI clinical research 2002–2003: the year in review Michael Camilleri  Clinical Gastroenterology and Hepatology  Volume 1, Issue 6, Pages 415-420 (November 2003) DOI: 10.1016/S1542-3565(03)00220-9

Figure 1 Recurrence of colorectal polyps in patients cured of colorectal cancer. Aspirin (325 mg) reduces the number of polyps relative to placebo, especially the proportion of patients with >1 recurrent adenoma. Data from Sandler et al.3 Clinical Gastroenterology and Hepatology 2003 1, 415-420DOI: (10.1016/S1542-3565(03)00220-9)

Figure 2 Maintenance of remission in patients with Crohn’s disease treated with infliximab. Note the significant advantage in proportion in clinical remission (CDAI <150) or in clinical response at week 54. Note also that, during 50 weeks of treatment, there is no significant advantage of dose escalation to 10 mg/kg relative to maintaining the same dose at 5 mg/kg. Reproduced with permission from Hanauer et al.10 Clinical Gastroenterology and Hepatology 2003 1, 415-420DOI: (10.1016/S1542-3565(03)00220-9)

Figure 3 Effect of adefovir dipivoxil on the change in HB virus DNA relative to placebo in patients with chronic hepatitis B virus infection. Reproduced with permission from Hadziyannis et al.16 Clinical Gastroenterology and Hepatology 2003 1, 415-420DOI: (10.1016/S1542-3565(03)00220-9)

Figure 4 Comparison of the efficacy of peginterferon and interferon with or without ribavirin in patients with chronic hepatitis C virus infection. End-of-treatment and sustained response outcomes show clear advantage of combination of peginterferon with ribavirin compared to the other 2 regimens. Note the remarkable sustained virologic response of 60% in the combination treatment group. Reproduced with permission from Fried et al.18 Clinical Gastroenterology and Hepatology 2003 1, 415-420DOI: (10.1016/S1542-3565(03)00220-9)

Figure 5 Effect of imatinib on tumor burden in a patient with a gastrointestinal stromal tumor. Reproduced with permission from Demetri et al.20 Clinical Gastroenterology and Hepatology 2003 1, 415-420DOI: (10.1016/S1542-3565(03)00220-9)